Moreover, the momentum for IPSC is fast paced, as the stock currently has a beta of 1.77. This indicates that the stock moves 77% higher than the market in either direction. Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time. Everyone likes betting on fast-moving trending stocks, but i ...

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth po ...

PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de Barcelona in Barcelona, Spain. The presentations will highlight data supporting the company’ ...

Century Therapeutics, Inc. (IPSC) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 387.10%. A quarter ago, it was expected that this company would post a loss of $0.45 per share when it actually produced a loss of $0.43, delivering a surprise of 4.44%.Over the last four quarters, ...

Table of Contents For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40498 Century Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delawar ...

Enhanced preclinical pipeline and platform aiming to expand and multiply cell therapy value Enhanced · Four potentially transformative Preclinical · Leading programs focus on iPSC- programs engineered with industry- derived 'tunable' CD4+/CD8+ aß T cells Pipeline leading Allo-Evasion™ 5.0 Selective expansion to non-immune . Century effector cells in high impact diseases Therapeutics: Concentrating clinical focus with CNTY-101 on autoimmune disorders with transformational Clear focus on potential Concentrate ...

文章核心观点 世纪治疗公司公布2025年第一季度财务业绩和业务亮点，在临床前管线、iPSC平台和制造能力方面取得进展，有望推进诱导多能干细胞（iPSC）衍生细胞疗法开发，为利益相关者创造价值 [1][2] 2025年第一季度及近期亮点 CNTY - 101在自身免疫性疾病方面 - 2025年3月，CALiPSO - 1试验开始对患者给药，评估CNTY - 101治疗B细胞介导自身免疫性疾病的潜力 [6] - 美国5个临床试验点已启动，预计2025年开设更多美国站点，部分欧洲国家站点激活活动正在进行，预计2025年下半年开始招募患者 [6] - CARAMEL IIT试验CTA获批，预计2025年年中开始，该试验由教授Georg Schett和Andreas Mackensen牵头，弗里德里希 - 亚历山大大学埃尔朗根 - 纽伦堡分校赞助 [6] - 公司有望在2025年底公布CNTY - 101的临床数据 [6] CNTY - 308和其他临床前项目 - 公司预计2025年年中启动CNTY - 308的IND启用研究，以支持B细胞介导的自身免疫性疾病和恶性肿瘤的预期临床试验 [5][11] - 在正在进行的美国基因与细胞治疗学会（ASGCT）第28届年会上，公司展示临床前细胞疗法管线数据，表明对CAR - iT和CAR - iNK细胞的某些工程改造可提高iPSC衍生免疫疗法的抗肿瘤活性，还展示了同种异体iPSC衍生靶向CD4 + / CD8 + ab CAR - T细胞的生成特征 [4] - 公司推进CNTY - 341和首个实体瘤CAR - iT研究项目，这些项目以先进的iPSC衍生“可调”CD4 + / CD8 + ab T细胞为基础，并采用公司专有的免疫逃逸技术Allo - Evasion™ 5.0，同时利用iPSC分化为非免疫效应细胞的专业知识，在高影响力治疗领域寻求机会 [11] 2025年第一季度财务结果 - 截至2025年3月31日，现金、现金等价物和有价证券为1.858亿美元，低于2024年12月31日的2.201亿美元，公司估计这些资金可支持运营至2026年第四季度 [11] - 2025年第一季度通过与百时美施贵宝的合作协议获得1.092亿美元合作收入，而2024年同期为90万美元，该合作协议于2025年3月12日终止 [11] - 2025年第一季度研发费用为2660万美元，高于2024年同期的2340万美元，主要因临床试验成本增加和临床前项目推进 [11] - 2025年第一季度一般及行政费用为840万美元，低于2024年同期的870万美元，主要因工资和福利费用减少 [11] - 2025年第一季度净收入为7660万美元，而2024年同期净亏损2810万美元 [11] 公司概况 世纪治疗公司是一家临床阶段的生物技术公司，利用细胞重编程、基因工程和制造方面的专业知识，开发针对自身免疫性疾病和癌症的iPSC衍生细胞疗法，致力于开发现货型细胞疗法，以扩大患者获取途径并改善疾病治疗 [9]

Wall Street expects a year-over-year increase in earnings on higher revenues when Century Therapeutics, Inc. (IPSC) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they mi ...

PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. The presentations will highligh ...

PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that company management will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss details and data for its prioritized preclinical cell therapy programs targeting autoimmune diseases and cancer. The event will feature disc ...